RNS Number : 7856R
Genus PLC
04 March 2019

4 March 2019

Genus plc

Director/PDMR Shareholding

Genus plc (LSE: GNS) announces that, further to the vesting of contingent rights over ordinary shares in Genus on 5 January 2019 under an individual restricted stock award agreement, Dr. Nate Zwald, a member of the Genus Executive Leadership Team, sold ordinary shares in Genus on 1 March 2019, on the London Stock Exchange to offset income tax and social security liabilities due on the exercise, and retained the balance of ordinary shares.

The below notification made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of contingent rights exercised and ordinary shares sold.

For further information please contact:

Genus:

Vaughn Walton, Interim Deputy Company Secretary Tel: +44 (0)1256 347100

Table A - GELT Restricted Stock Award Exercise

<table>
<tr><td>1.</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Dr. Nate Zwald</td></tr>
<tr><td>2.</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a.</td><td>Position/status</td><td>Chief Operating Officer, Genus ABS Dairy</td></tr>
<tr><td>b.</td><td>Initial notification /Amendment</td><td>Initial notification</td></tr>
<tr><td>3.</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>Genus plc</td></tr>
<tr><td>b.</td><td>LEI</td><td>54930022EOITNKSIGH56</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument Identification code</td><td>Ordinary shares of 10p each

GB0002074580</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Acquisition of shares following exercise of 3,612 contingent rights under an individual restricted stock award agreement.</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>0p</td><td>3,612</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
• Aggregated volume
• Price</td><td><table><tr><td>Average price(s)</td><td>Total volume(s)</td></tr><tr><td>0p</td><td>3,612</td></tr></table></td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>2019-03-01</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>Outside a trading venue.</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the</td><td>Ordinary shares of 10p each</td></tr>
</table>

<table>
<tr><td>a.</td><td>Financial instrument, type of instrument Identification code</td><td>GB0002074580</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Sale of 1,293 shares arising from the exercise of contingent rights under an individual restricted stock award agreement, to offset income tax and social security liabilities due on the exercise.</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>2,198.0404p</td><td>1,293</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
Aggregated volume
Price</td><td><table><tr><th>Average price(s)</th><th>Total volume(s)</th></tr><tr><td>2,198.0404p</td><td>1,293</td></tr></table></td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>2019-03-01</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>London Stock Exchange, Main Market (XLON)</td></tr>
</table>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHUSAVRKRAORAR